QPharma, a leading regulatory compliance and brand solutions company, has introduced its QLaunch™ service, a comprehensive solution for pharmaceutical, medical device, and biotech companies preparing for a new product launch.
QPharma recently conducted a survey of 300 U.S. physicians across various specialties and sub-specialties to gather the latest available data about what covered recipients, specifically physicians, understand about the Physician Payment Sunshine Act and its requirements.
As the U.S. federal government shutdown enters its second week, life sciences decision makers may be uncertain as to how the shutdown affects the Food and Drug Administration and therefore, how it will impact application reviews, FDA inspections, and other compliance-related activities.
Learn From Our UDI Experts!
On Friday, September 20, the final Unique Device Identification (UDI) rule was issued by the Food and Drug Administration in conjunction with the 2013 UDI Conference in Baltimore, Maryland.
As regulatory scrutiny on our industry increases, it’s critical for life science organizations to implement effective compliance training curricula that foster behavior change.
QDevice, the medical device consulting division of QPharma, is advising its clients and all medical device manufacturers to prepare for compliance with the Unique Device Identification (UDI) final rule, which is expected to be passed this year.
QPharma, a leading regulatory consulting and brand solutions firm for life sciences, has announced the appointment of Maria A. Galdos to the position of Senior Manager, Healthcare Compliance.
QPharma has announced its acquisition of MD Mindset, LLC, a leading physician research firm focused on improving pharmaceutical sales force and marketing effectiveness.
QPharma has announced the appointment of Dr. Peter J. Shaw to the position of Chief Medical Officer.